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Abstract 
Introduction: The efficacy of chemotherapy can be compromised by drug resistance.  This study was undertaken to describe the resistance 
profiles and fluoroquinolone resistance mechanism of non-typhoidal Salmonella (NTS) isolated from humans and poultry in West Bank, 
Palestine.  
Methodology: One hundred and fifty-one isolates of NTS, obtained from humans (71) and poultry (80), collected between September 2005 
and January 2007, were tested for susceptibility to ampicillin, gentamicin, tetracycline ceftriaxone, nalidixic acid and ciprofloxacin. Mutation 
patterns within gyrA were determined by direct sequencing or by digestion of PCR-amplified DNA fragments with the restriction enzyme 
HinfI.  
Results: Resistance rates among human and poultry isolates were respectively 59% and 51% for ampicillin, 31% and 10% for gentamicin, 
59% and 80% for tetracycline, 59% and 45% for nalidixic acid, and 30% and 15% for ciprofloxacin. All the isolates were susceptible to 
ceftriaxone. Mutations at positions 83 and/or 87 were detected in gyrA of isolates with resistance to nalidixic acid. Isolates which were 
resistant to nalidixic acid but susceptible to ciprofloxacin had a single gyr A gene mutation at point 87.  This gene mutation was sufficient to 
induce a new phenotype (6 isolates) with decreased susceptibility to ciprofloxacin.  
Conclusion: Mutations in gyrA at positions 83 or 87 were the most prevalent mutation pattern of fluoroquinolone resistant NTS isolates but 
other unknown mechanisms are also present. Continued surveillance of antimicrobial resistance among NTS isolates is needed to mitigate the 
increasing prevalence of quinolone resistance. 
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Introduction 
Infections with non-typhoidal Salmonella (NTS) 
are a significant cause of illness and death worldwide. 
About 1.4 million cases are observed in the United 
States annually, out of which 600 are fatal [1]. NTS 
are also among the most common causes of invasive 
bacterial childhood disease [2-3] for which 
antimicrobial chemotherapy can be lifesaving. 
Antimicrobial resistance to several classes of 
traditional first-line drugs has emerged in recent 
decades. Fluoroquinolones [4-5] are normally used to 
treat invasive gastrointestinal infections in adults. 
Unfortunately, NTS with reduced fluoroquinolone 
susceptibility ( > 0.06mg/L) has increased during 
recent years in many countries [2,4-8].  
Animals are the main reservoirs for NTS. The 
transmission of this microorganism occurs by the 
consumption of inadequately cooked or pasteurized 
foods of animal origin, including poultry, beef, fish, 
eggs, and dairy products [9]. The incidence of human 
salmonellosis varies with geographic, socioeconomic, 
and environmental factors [10]. The present study 
aimed to obtain a snapshot of NTS resistance in West 
Bank, Palestine. To the best of our knowledge this part 
of the world has not previously been surveyed for this 
type of resistance. 
 
Methodology 
Bacterial strains and study population 
A total of 151 NTS isolates were obtained from 
humans (71) and poultry (80). The human isolates 
were collected from children attending outpatient 
clinics in Bethlehem and Al-Makassed Hospital in 
East Jerusalem between September 2006 and October 
2007. The poultry isolates were provided by the 
Central Laboratory for Public Health at Ramallah, 
Palestine, collected between September 2005 and 
January 2007. 
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Antimicrobial susceptibility testing 
Antimicrobial susceptibility of NTS isolates was 
determined using the disc diffusion method according 
to Clinical Laboratory Standard Institute (CLSI) 
guidelines [11]. Tested antibiotics were ampicillin 
(10µg), tetracycline (30µg), ciprofloxacin (5µg), 
nalidixic acid (30µg), gentamicin (10µg), and 
ceftriaxone (30µg) (all from Oxoid, Bakingstoke, 
United Kingdom). According to CLSI guidelines, 
susceptibility profiles are S >19, I 14-18, R < 13 for 
nalidixic acid and S > 21, 16-20, R < 15 for 
ciprofloxacin.  According to CLSI, fluoroquinolone-
susceptible strains that test resistant to nalidixic acid 
may be associated with clinical failure or delayed 
response in fluoroquinolone treated patients [11].  
 
gyrA gene amplification, restriction and sequencing 
PCR and restriction of amplicons by HinfI enzyme 
was performed according to the procedure outlined by 
Kariuki [12]. Briefly, the template DNA was prepared 
from each strain by boiling a fresh colony in 200µl of 
sterile distilled water for 15 minutes at 95oC, followed 
by centrifugation at 14,000 rpm for 2 minutes. PCR 
reaction conditions consisted of 50 ng of DNA and 
100 nM of each primer, GyrA-f; 
ATGAGCGACCTTGCGAGAGAAATTACACCG 
and GyrA-r; 
TTCCATCAGCCCTTCAATGCTGATGTCTTC 
(Syntezza, Jerusalem, Israel) in a buffer composed of 
10 mM Tris-HCL (pH 8.3), 50 mM KCL, 1.5 mM 
MgCl2, 200 µM deoxynucleoide triphosphate mixture, 
and 1U of Taq polymerase (Promega, Madison, WI, 
USA) in a final volume of 25 µl. The amplification 
program was set in the Minicycler TM, (MJ Research, 
Waltham, USA) to run an initial denaturation of 4 
minutes at 94oC followed by 35 cycles, each at 94°C 
for 30 seconds, 55°C for 30 seconds, and 72oC for 30 
seconds, with a final extension step of 72°C for 10 
minutes. Restriction was achieved by combining 2 µl 
HinfI (5 U) (Gibco, New York, USA) with 10 µl PCR 
product in a total volume of 20 µl buffer and 
incubating for 1 to 2 hours at 37°C.  After digestion, 
electrophoresis was carried out using 2% agarose at 80 
volts for 10 minutes, then at 120 volts for 30 minutes 
against a 50 bp ladder, viewed on a UV viewer and 
photographed by a Polaroid camera. 
The amplicons containing gyrA gene were purified 
using MinElute PCR purification kit (Qiagen, Hilden, 
Germany) and the inserts were sequenced by a 
dideoxy chain termination method on an ABI PRISM 
Model 301 Sequence Instrument, Foster City, CA, 
USA at Bethlehem University, Bethlehem, Palestine.  
 
Results 
Antimicrobial susceptibility  
The results of the antimicrobial susceptibility 
testing among human and poultry NTS isolates were 
respectively 59% and 51% for ampicillin, 31% and 
10% for gentamicin, 59% and 80% for tetracycline, 
59% and 45% for nalidixic acid, and 30% and 15% for 
ciprofloxacin. All the isolates were susceptible to 
ceftriaxone. Of the 151 NTS isolates three main 
susceptibility patterns were identified for quinolones: 
71 (47%) were sensitive to both nalidixic acid and 
ciprofloxacin (zone size > 19 mm and > 21 mm 
respectively), 47 (31%) were resistant to nalidixic acid 
(zone size < 13 mm) but susceptible to ciprofloxacin 
(zone size > 21 < 13 mm and < 15 mm) and 33  
Table 1. Antibiotic resistance among nontyphoid Salmonella spp. isolated from clinical and food sources 
 %Resistance 
Source AMP CHL CIP CRO GEN NAL SXT TE 
Human Isolates (n = 71) 59.1 8.4 29.6 0 30.9 59.1 9.9 59.1 
Poultry Isolates (n = 80) 51.3 5 15 0 10 45 5 80 
Ampicillin (AMP), Tetracycline (TE), Ciprofloxacin (CIP), Nalidixic acid (NAL), Gentamicin (GEN), Chloramphenicol (CHL), Trimethpprimsulfa-
methoxazole (SXT), Ceftriaxone (CRO). 
 
 
 
Table 2. Patterns of susceptibility to quinolones among non-typhi Salmonella enterica spp. isolated from human and poultry 
Source of Specimen 
Pattern of Susceptibility to Quinolones 
SS RS RR 
Human Isolates (71) 27 (38%) 23 (32.4%) 21 (29.6%) 
Poultry Isolates (80) 41 (51.3%) 24 (30%) 12 (15%) 
SS: susceptible to nalidixic acid and ciprofloxacin, RS: resistant to nalidixic acid but susceptible to ciprofloxacin, RR: resistant to both nalidixic acid and 
ciprofloxacin. 
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Figure 1. Scatter plot showing the relation between the zone diameters (mm) of ciprofloxacin and nalidixic acid for all isolates of 
non typhoid salmonella spp. The vertical and horizontal lines in the scatter plot indicate the recommended CLSI breakpoints for the 
two antibiotics. Interpretation of zone daiameters (CLSI, M100-S20): Nalidixic acid: S >19, I 14-18, R < 13, Ciprofloxacin: S >21, 
16-20, R < 15 
Figure 2. Agarose gel electrophoresis of HinfI restriction fragment length polymorphism: Lane 1, 50 bp ladder DNA; Lane 2, 
undigested 630-bp PCR product; Lane 3, digests from quinolone sensitive isolate; Lane 4, digests from quinolone resistant isolate 
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(21.8%) were resistant to both nalidixic acid and 
ciprofloxacin (zone size < 13 mm and < 15 mm 
respectively). Four isolates were intermediate for 
nalidixic acid (between 15 and 20mm zone size) but 
remained susceptible to ciprofloxacin. Since NTS is an 
invasive disease that is treated with fluoroquinolones, 
a scatterplot was constructed to show the relationship 
between the zone diameters of nalidixic acid and 
ciprofloxacin (Figure 1). 
 
PCR products and point mutations in gyrA 
The nucleotide sequences of the 630bp DNA 
fragment corresponding to the gyrA gene from 
nalidixic acid and ciprofloxacin- resistant isolates 
showed mutations in the codons corresponding to 
amino acids 83 (TCC to TTC) or 87 (GAC to TAC) or 
both in comparison with those of the quinolone-
susceptible isolates, indicating a serine to 
phenylalanine substitution and tyrosine to aspartic acid 
substitution, respectively.  
 
Hinf1 restriction fragment length polymorphisms  
PCR products for all NTS isolates consistently had 
the mobility expected for a 630 bp DNA fragment 
(Figure 1, lanes 2). HinfI digestion was predicted to 
yield three products of DNA fragments with sizes of 
130, 150 and 350 bp. This was seen with DNA from 
isolates that are sensitive to quinolone (Figure 1, lane 
32). However, mutation at the sequence corresponding 
to amino acid position 83, as found in isolates that are 
resistant to nalidixic acid and ciprofloxacin, removes 
one HinfI site so that digestion generated only two 
fragments with sizes of 480 and 130 bp (Figure 2, lane 
4).  
 
Discussion 
Antibiotic-resistant NTS, especially those with 
fluoroquinolone resistance, are increasingly isolated 
and are a serious problem in many areas. Many strains 
are multi-drug resistant: Finland [7], Mexico [13], 
Vietnam [14] and Israel [15] all have reported 
nalidixic acid resistance rates ranging from 20% to 
54%, and even higher prevalence rates have been 
reported in the Belgium [2]. Data from the present 
study indicate an extremely high rate: 59.2% and 45% 
of nalidixic acid resistant NTS among human and 
poultry isolates respectively in Palestine. However, 
resistance to nalidixic acid may not predict resistance 
to fluoroquinolones in NTS, unlike the situation in 
Salmonella Typhi [16].  In this study high-level 
resistance of NTS to ciprofloxacin was shown in a 
lower percentage of the isolates: 29.6% and 15% in 
human and poultry isolates respectively. This rate of 
resistance to ciprofloxacin is probably, in part, a 
consequence of the administration of fluoroquinolones 
to food animals [8] and has major therapeutic 
implications, insofar as fluoroquinolone resistance is 
associated with multi-drug resistance [17-18]. Nearly 
half of the nalidixic acid-resistant isolates were also 
resistant to at least two or more of: ampicillin, 
tetracycline or gentamicin. Nevertheless, resistance to 
ceftriaxone was not related to resistance to other 
agents. Therefore, ceftriaxone may provide an 
alternative therapy for use in patient populations likely 
to be infected with multi-resistant NTS.  
Studies on the quinolone resistance determining 
region revealed that mutation in gyrA led to resistance 
to fluoroquinolone [19]. To address this aspect, gyrA 
genes from quinolone isolates were amplified by PCR, 
and the sequence variation in the quinolone resistance 
determining region defined and compared to 
quinolone-sensitive isolates.  Results showed that gyrA 
from the resistant isolates had mutations at codons for 
amino acids 83 or 87 or both. The first of these 
mutations led to replacement of serine-83 by 
phenylalanine, whereas the second mutation led to 
replacement of aspartic acid-87 by tyrosine. These 
results are comparable to the findings of other studies 
conducted in different countries [20-22]. In this study,  
the strains that were resistant to ciprofloxacin showed 
mutations at codons for amino acids 83 or 87 or both. 
Interestingly, a group of nalidixic acid-resistant 
isolates showed decreased susceptibility to 
ciprofloxacin (ciprofloxacin zone diameter < 25 mm) 
with a point mutation in the gyrA gene (Figure 1).  
Isolates resistant to nalidixic acid and ciprofloxacin 
had two mutations in the gyrA gene. Therefore, there 
must be an association between mutations in gyrA and 
low-level ciprofloxacin resistance. A limitation of the 
study is that only mutations in gyrA were looked at 
and it is possible, as in S. Typhi, that mutations in 
other topoisomerase genes could also be present [23]. 
In conclusion, the high frequency of 
fluoroquinolone resistance among NTS has clearly 
emerged as a serious problem in Palestine. There is 
considerable variation in the phenotype of 
fluoroquinolone resistance which may represent the 
influence of unknown resistance mechanisms. It is 
necessary to conduct continuous surveillance of this 
problem and link the minimum inhibitory 
concentration and molecular data to clinical outcome 
to generate accurate data and identify appropriate 
therapies for specific infections. 
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